poly ADP-ribose polymerase (PARP) inhibitor for COVID-19: living meta-analysis of clinical studies

display ongoing

results: demonstrated suggested inconclusive safety concern ongoing study

	multiple myeloma - 2nd line (L2)	metastatic/advanced OC (mOC) - maintenance (M)

	ovarian cancer (OC)	metastatic/advanced OC (mOC) - maintenance (M)
poly ADP-ribose polymerase (PARP) inhibitor
niraparib	ENGOT-OV16/NOVA
olaparib	PAOLA-1/ENGOT-ov25 SOLO 1 SOLO2/ENGOT-Ov21 SOLO 3 Ledermann
rucaparib	ARIEL3 ARIEL4	ATHENA-COMBO ...

Study type: